Chimerix Inc (CMRX) Expected to Post Earnings of -$0.38 Per Share

Wall Street analysts expect that Chimerix Inc (NASDAQ:CMRX) will report ($0.38) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Chimerix’s earnings, with the highest EPS estimate coming in at ($0.33) and the lowest estimate coming in at ($0.43). Chimerix reported earnings of ($0.41) per share in the same quarter last year, which would indicate a positive year over year growth rate of 7.3%. The firm is scheduled to issue its next earnings results on Thursday, March 7th.

On average, analysts expect that Chimerix will report full-year earnings of ($1.51) per share for the current fiscal year, with EPS estimates ranging from ($1.57) to ($1.47). For the next fiscal year, analysts expect that the business will report earnings of ($1.53) per share, with EPS estimates ranging from ($1.85) to ($1.38). Zacks’ EPS averages are an average based on a survey of analysts that follow Chimerix.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.09. The company had revenue of $0.37 million during the quarter, compared to the consensus estimate of $0.97 million. Chimerix had a negative net margin of 1,752.41% and a negative return on equity of 36.40%.

A number of equities analysts have recently commented on the stock. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a report on Wednesday, November 14th. Cowen reaffirmed a “hold” rating and set a $6.00 price objective on shares of Chimerix in a report on Thursday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Chimerix in a report on Friday, September 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $6.50.

Shares of NASDAQ:CMRX traded up $0.02 during midday trading on Tuesday, reaching $3.25. 298,844 shares of the company’s stock were exchanged, compared to its average volume of 188,747. The company has a market capitalization of $166.88 million, a price-to-earnings ratio of -2.15 and a beta of 1.17. Chimerix has a 12 month low of $3.11 and a 12 month high of $5.94.

Several large investors have recently added to or reduced their stakes in CMRX. Point72 Asset Management L.P. bought a new position in shares of Chimerix during the 3rd quarter worth about $3,890,000. Opaleye Management Inc. increased its position in shares of Chimerix by 91.7% during the 2nd quarter. Opaleye Management Inc. now owns 1,150,000 shares of the biopharmaceutical company’s stock worth $5,474,000 after purchasing an additional 550,000 shares in the last quarter. Artal Group S.A. increased its position in shares of Chimerix by 100.0% during the 3rd quarter. Artal Group S.A. now owns 1,000,000 shares of the biopharmaceutical company’s stock worth $3,890,000 after purchasing an additional 500,000 shares in the last quarter. Morgan Stanley increased its position in shares of Chimerix by 28.8% during the 3rd quarter. Morgan Stanley now owns 2,041,150 shares of the biopharmaceutical company’s stock worth $7,940,000 after purchasing an additional 456,290 shares in the last quarter. Finally, BlackRock Inc. increased its position in shares of Chimerix by 6.2% during the 3rd quarter. BlackRock Inc. now owns 3,711,445 shares of the biopharmaceutical company’s stock worth $14,439,000 after purchasing an additional 215,268 shares in the last quarter. 72.91% of the stock is owned by institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Further Reading: Quiet Period

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit